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The Effect of Influenza Vaccination on Mortality and 
Risk of Hospitalization in Patients With Heart Failure: 
A Systematic Review and Meta-analysis
Sanjay Poudel,1 Fadi Shehadeh,1 Ioannis M. Zacharioudakis,2 Giannoula S. Tansarli,1 Fainareti N. Zervou,1,3 Markos Kalligeros,1 Robertus van Aalst,4,5 
Ayman Chit,4,6 and Eleftherios Mylonakis1
1Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, Rhode Island; 2Division of Infectious Diseases and Immunology, Department of Medicine, NYU School 
of Medicine, New York, New York; 3Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island; 4Regional Epidemiology and Health Economics, Sanofi 
Pasteur, Swiftwater, Pennsylvania; 5Faculty of Medical Sciences, University of Groningen, Groningen, the Netherlands; 6Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Background. Influenza is a major cause of morbidity and mortality in patients diagnosed with heart failure. The aim of this 
study was to evaluate the effectiveness of influenza vaccination in this population in terms of reduction in all-cause mortality and 
rate of hospitalization.
Methods. We conducted a systematic review and meta-analysis using PubMed and EMBASE entries from January of 2000 
through April 2018. Publication bias was examined using the Egger’s regression test. Statistical heterogeneity was examined using the 
Higgins I2 statistic. Subgroup analyses were performed to examine the effect of vaccination during the influenza and noninfluenza 
seasons.
Results. We identified 8 studies that included a total of 82 354 patients with heart failure. In patients with heart failure who were 
vaccinated against influenza, we found a reduced risk of all-cause mortality (hazard ratio [HR], 0.69; 95% confidence interval [CI], 
0.51–0.87). No evidence of publication bias was found, and the effect was more pronounced during influenza season (HR, 0.49; 95% 
CI, 0.30–0.69), compared with noninfluenza season (HR, 0.79; 95% CI, 0.68–0.89). In terms of heart failure hospitalizations, we did 
not identify a statistically significant difference between the cohorts (HR, 0.62; 95% CI, 0.00–1.23).
Conclusions. Influenza vaccination was associated with a decreased risk of all-cause mortality in patients with heart failure, and 
this effect was more prominent during the influenza season.
Keywords.  all-cause mortality; heart failure; hospitalization; influenza vaccination.
Despite advancements in the medical field, influenza remains 
a major cause of infectious morbidity and mortality. Across 5 
influenza seasons from 2010 to 2015, the Centers for Disease 
Control and Prevention (CDC) estimated the number of in-
fluenza infection cases in the United States to range from 9.2 
million in the 2011–2012 flu season to 35.6 million in the 2012–
2013 influenza season [1]. More recently, during the 2016–2017 
season, there were 30.9 million cases of influenza infection, 
with approximately 600 000 hospitalizations [1]. Although the 
incidence of influenza infection was evenly distributed across 
all age groups, more than two-thirds of patients hospitalized 
due to influenza and more than two-thirds of influenza-related 
deaths were among patients older than 65 years of age [1].
A number of studies have shown the role of influenza in 
cardiovascular complications, including acute myocardial in-
farction [2], stroke [3], and the role of influenza vaccine in 
preventing such events [4, 5]. To more accurately depict the 
burden of influenza infection, the CDC has expanded the tradi-
tional model of pneumonia- and influenza-related deaths (P&I 
deaths). Deaths secondary to respiratory and cardiovascular 
complications (R&C deaths) are now included, highlighting the 
effect of influenza infection in the exacerbation of chronic res-
piratory and cardiovascular conditions [1]. Notably, the R&C 
deaths were estimated to be 3 times higher than the rate for P&I 
deaths [1].
Heart failure accounts for 9% of the total cardiovascular 
mortality [6]. In the United States, >6.5 million individuals are 
diagnosed with heart failure each year, with approximately 1 
million new cases and 68 000 heart failure–related deaths per 
year [6]. Heart failure etiologies vary, but the majority of cases 
are secondary to chronic heart diseases like hypertension and 
coronary artery disease [7]. The incidence approaches 21 per 








roningen user on 21 M
ay 2019
2 • ofid • Poudel et al
triples with each 10-year increase in age from 65 to 85 years in 
males and females, respectively [8]. Respiratory infections are 
closely related to heart failure exacerbation and may lead to 
high in-hospital mortality, as shown by a large study of 48 612 
patients with heart failure [9]. However, there have been limited 
studies focusing on the association between heart failure and in-
fluenza vaccination, and most of these studies included elderly 
patients without accounting for cardiovascular morbidity or 
heart failure at baseline [10–12]. Reports have suggested a pro-
tective role of influenza vaccination on the prognosis of patients 
with heart failure [13], but no large randomized controlled 
trials or a meta-analysis have been conducted to quantitatively 
estimate the effectiveness of influenza vaccination in patients 
with heart failure. We conducted a systematic review and meta-
analysis to evaluate the available data on morbidity and mor-
tality outcomes in vaccinated and nonvaccinated patients with 
heart failure.
METHODS
Our systematic review and meta-analysis followed the 
guidelines for the Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE) [14].
Literature Search
A systematic literature search was conducted for publications 
in the PubMed and EMBASE databases from January 2000 to 
March 2018. The following search terms were used: (“Influenza” 
OR “Flu” OR “Vaccine” OR “Vaccination”) AND (“Heart 
Failure” OR “Congestive Heart Disease” OR “CHF” OR “HF” 
OR “Cardiac Failure” OR “Ventricular Failure” OR “Myocardial 
Dysfunction”). Articles not available in English were excluded. 
Duplicate studies from the 2 databases were excluded using 
the Systematic Review Accelerator (SRA), which is considered 
sensitive and specific [15]. Two investigators (S.P. and F.S.) in-
dependently identified and reviewed the titles and abstracts of 
the published studies that appeared in the search. Potentially 
relevant studies were reviewed in full text. We reviewed the ref-
erence lists of relevant articles to identify additional studies.
Eligibility Criteria
To be eligible for our meta-analysis, studies had to fulfill the 
following criteria: (1) the study population included patients 
diagnosed with heart failure; (2) the study provided compar-
ative information available in 2 cohorts—influenza-vaccinated 
and -nonvaccinated patients; (3) vaccination was administered 
within a year of study enrollment; (4) outcomes reported in-
cluded all-cause mortality or hospitalization.
Outcomes of Interest
The outcomes of interest included all-cause mortality and the 
rate of hospitalization among patients with heart failure who 
were vaccinated and patients who were not vaccinated.
Data Extraction
Data from the eligible studies were extracted independently by 
2 reviewers (S.P. and F.S.). We extracted the following informa-
tion: author, year of publication, study design, country, study 
duration, follow-up period, study population and size, hazard 
ratio and/or risk ratio of mortality, and hospitalization in 
vaccinated and nonvaccinated study groups. Any discrepancies 
between the reviewers were resolved with discussions and con-
sensus. Heart failure diagnosis was accepted as per the indi-
vidual studies’ definitions.
Quality Assessment
We used the Newcastle Ottawa Scale (NOS) to assess the meth-
odological quality of observational cohort studies [16]. Two 
investigators (S.P.  and F.S.) independently assessed the risk 
of bias. As our primary outcomes of interest were all-cause 
mortality and the rate of hospitalization among patients with 
heart failure, all 8 stars of the Newcastle Ottawa Scale could 
be assigned. Two investigators (S.P.  and F.S.) independently 
assessed the risk of bias. Studies with an NOS score ≥7 were 
considered of adequate quality, whereas those with a score <7 
were considered of inadequate quality. One study [17] was 
awarded an NOS score of 7, whereas the rest of the studies were 
awarded a score of 8.
Data Analysis
All statistical analysis was done using STATA, version 15.1 
(StataCorp LLC, College Station, TX). We investigated the effect 
of influenza vaccination on the risk of mortality and hospitali-
zation in the heart failure population. A subgroup analysis was 
performed to compare the effects of vaccination in the influ-
enza season and noninfluenza season. We calculated a pooled 
hazard ratio (HR) with 95% confidence interval (CI) using the 
data reported in the individual studies. The studies that did not 
provide extractable data were not included in the meta-analysis 
and are discussed separately as part of the systematic review. 
Testing for heterogeneity was performed using the Higgins I2, 
which measures the percentage of variation between the studies 
[18]. The DerSimonian and Laird random-effects model was 
used to pool the HR due to expected heterogeneity among the 
individual studies [19]. Publication bias was assessed using 
Egger’s regression test. Statistical significance was set at .05.
RESULTS
Study Selection and Characteristics
A systematic search of the PubMed and EMBASE databases 
yielded 661 and 2801 articles, respectively (total n  =  3462). 
After exclusion of duplicates and articles that were not avail-
able in the English language, the remaining 2674 articles were 
screened by title and abstract, and we identified 20 articles that 
were evaluated in full text. Of those, we excluded 4 studies 
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hospitalization. We also excluded 8 studies that focused on a 
study population different than that specified in our eligibility 
criteria (4 of these studies focused on an elderly population 
without heart failure diagnosis at baseline, whereas the re-
maining 4 studies focused on patients with acute coronary syn-
drome, chronic kidney disease, diabetes mellitus, and chronic 
obstructive pulmonary disease, all without a heart failure di-
agnosis at baseline). No further studies were identified after a 
manual search of references. The detailed search process and 
study selection are depicted in Figure 1. In this analysis, we in-
cluded 8 observational cohort studies [17,20–26] that fulfilled 
our criteria. The included studies were conducted in the fol-
lowing countries: 2 in Spain [20, 21] and 1 each in Israel [23], 
Taiwan [24], the United States [26], the United Kingdom [17], 
and Turkey [22]. In addition, 1 study reported data from 47 
countries, including the United States [25]. The study period for 
3 of the studies spanned the 2009 influenza pandemic [17, 20, 
25], with 1 study identifying the inclusion of pandemic infection 
in the study population [20]. The International Classification 
of Diseases (ICD) coding was used to define heart failure in 3 
studies [17, 21, 24], whereas the International Classification of 
Primary Care (ICPC) was used in 1 study [20]. Also, 1 study 
included patients with a reduction in left ventricular ejection 
fraction [25], whereas no specific definition of heart failure was 
found in the remaining 3 studies [22, 23, 26].
The total study population included in our analysis from 
these 8 studies was 82 354. The mean age of the study popu-
lation (range) was ≥65 (65–76) years in all studies, except in 1 
study [22], which had a mean age of <65 years. Study duration 
varied from 2 years to 20 years. Among the included studies, 6 
studies reported information on all-cause mortality, whereas 4 
reported the risk of subsequent hospitalization. One study re-
ported 1-year all-cause mortality hazard ratio [25], 3 studies 
reported 4-year all-cause mortality hazard ratio in the influ-
enza and noninfluenza seasons separately [20, 21, 24], 1 study 
reported both 1-year and 4-year all-cause mortality hazard ratio 
[23], and the last study reported 1-year all-cause mortality odds 
ratio [26].
In terms of hospitalization, 1 study reported 1-year risk of 
hospitalization [22], 1 study reported 2-year risk of hospitaliza-
tion [25], and 1 study reported 4-year risk of hospitalization in 
the influenza and noninfluenza seasons separately [24]. The last 
study that reported hospitalization risk, Mohseni et al., followed 
a self-controlled study design in which the hospitalization rate 
among individuals with heart failure during the vaccination 
year was compared with the hospitalization rate in an adjacent 
Articles retrieved using the search term (n = 3462)
PubMed: 661
EMBASE: 2801
Studies screened after exclusion (n = 2674)
Studies retrieved for full-text evaluation (n = 20)
Potentially appropriate studies (n = 8)
Studies included in the systematic review and
meta-analysis (n = 8)
Language (not in English; n = 260)
Studies that are duplicates (n = 528)
Studies excluded on title and abstract reading
(n = 2654)
Articles that did not fulfill inclusion criteria (n = 12)
Articles added after manual search of  references
(n = 0)
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nonvaccination year for the same individual [17]. The vaccina-
tion year was determined based on vaccination status within 
12  months before each study year. A  summary of individual 
study characteristics is presented in Table 1.
We used the Newcastle Ottawa Scale to evaluate observational 
cohort studies. Most of the studies were based on electronic health 
records, and thus the cohort representation was considered ad-
equate. The 2 cohorts (vaccinated vs nonvaccinated) were com-
parable, and the baseline comorbidities were compared on all 
studies, with some using propensity score matching [20, 23, 
25] and some using multivariable adjustment [21, 22, 24, 26] 
to ensure that the cohorts were comparable. Records of influ-
enza vaccination were based on the recall of each individual, 
and as the recall duration was less than a year, the possibility 
of recall bias was considered to be low [27]. In terms of expo-
sure duration, as influenza vaccination effects may wane after 
6  months [28], even 1-year follow-up, which was followed in 
most studies, was considered adequate. All the included studies 
were considered of adequate quality based on the Newcastle 
Ottawa Scale.
Influenza Vaccination and Mortality
Four out of the 6 studies (16 751 patients) that reported data 
on mortality were included in the meta-analysis to evaluate the 
effect of influenza vaccination on mortality [21, 23–25]. There 
were another 2 studies that reported mortality outcome but 
could not be used in the meta-analysis because they reported the 
odds ratio instead of hazard ratio of mortality [26] or compared 
outcomes between consistently vaccinated and inconsistently or 
never-vaccinated individuals with heart failure during a 4-year 
study period [20]. Pooling of the 4 studies showed that influenza 
vaccination was associated with a decreased risk of mortality 
in individuals with heart failure 1 year after administration of 
the vaccine (HR, 0.69; 95% CI, 0.51–0.87) (Figure 2A). No ev-
idence of publication bias was detected by the Egger’s test for 
small study effects (P =  .190). Considerable statistical hetero-
geneity was detected between the included studies (I2 = 85.5%; 
Cochran Q value = 20.71; P < .01). In addition, we performed a 
subanalysis on 2 studies (6388 patients) that reported outcomes 
separately for the influenza and noninfluenza seasons (January 
to April for Diego et al., October to March for Liu et al., June 
to September for Diego et al., April to September for Liu et al., 
respectively) [21, 24]. The pooled hazard ratio of all-cause mor-
tality during the influenza season was 0.49 (95% CI, 0.30–0.69) 
(Figure 2B), and during the noninfluenza season, it was 0.79 
(95% CI, 0.68–0.89) (Figure 2C). Finally, we separately pooled 2 
studies that reported on patients with heart failure only and not 
chronic heart disease [23, 25], and we found a hazard ratio of 
0.81 (95% CI, 0.70–0.92) (Figure 2D).
Influenza Vaccination and Hospitalization
Two out of 3 studies (9055 patients) that reported data on hos-
pitalization secondary to heart failure could be pooled in a 
meta-analysis [22, 25]. We found that influenza vaccination was 
associated with lower heart failure hospitalization compared 
with nonvaccinated individuals with heart failure (HR, 0.62; 
95% CI, 0.00–1.23) (Figure 2E). However, the result was not sta-
tistically significant. Considerable heterogeneity was detected 
Table 1.  Study Characteristics

















1964 (501/1463) 75.8 ± 9.2/74.1 ± 10.6 56% /55% 12 months prior 
to study




8399 (1769/6630) 67.9 ± 10.1/62.7 ± 11.5 77.7%/80.2% 12 months prior 
to study




5048 (2760/2288) 74.8 ± 6.3/75.7 ± 7 58.3%/51.8% 12 months prior 
to each study 
year




1340 (860/480) 76.7 ± 6.7/75.5 ± 7.6 48%/46.3% 12 months prior 
to each study 
year




3229/2032 (1016/1016) 75.97 ± 9.67/76.53 ± 10.44 38.09%/39.67% 12 months prior 
to each study 
year




2516 (2087/429) 71.91 ± 10.55/68.3 ± 11.27 98.5%/98.4% 12 months prior 
to each study 
year




59 202 74.7 ± 11.3/74.7 ± 11.3 50.1%/50.1% 12 months prior 
to each study 
year




656 (265/391) 60 ± 14/63 ± 13 72%/72% 12 months prior 
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in this analysis (I2 = 97.1%; Cochrane Q value = 34.4; P < .01). 
Data presented in the study by Mohseni et  al. [17] could not 
be pooled, as a hazard ratio was not provided, and the authors 
reported a statistically significant decrease in incidence rate of 
heart failure hospitalization with influenza vaccination in heart 
failure individuals (incidence rate ratio [IRR], 0.71; 95% CI, 
0.68–0.75) (Table 2).
Two studies examined the association of influenza vacci-
nation with all-cause hospitalization in individuals with heart 
failure [17, 25]. In particular, Mohseni et al. [17] showed that 
the incidence rate ratio was significantly lower in the vaccinated 
group (IRR, 0.96; 95% CI, 0.95–0.98), as compared with the 
nonvaccinated group, whereas Vardeny et  al. [25] failed to 
show a statistically significant difference in all-cause hospital-
ization between the 2 groups (HR,  1.07; 95% CI, 0.97–1.18) 
(Table 2). Finally, in terms of cardiovascular hospitalization, 2 
studies reported a significant decrease in the risk of hospital-
ization with the administration of influenza vaccine [17, 24]. 
Mohseni et al. [17] reported an IRR of 0.73, and Liu et al. [24] 
reported a hazard ratio of 0.84 and 1.04 in the influenza season 
and noninfluenza season, respectively (Table 2).
DISCUSSION
In this study, we evaluated the effect of influenza vaccination on 
all-cause mortality and hospitalization rate among patients with 
DL Overall (I2 = 85.5%)











NOTE: Weights are from random-eects analysis
NOTE: Weights are from random-eects analysis





NOTE: Weights are from random-eects analysis
ES (95% CI) % Weight (DL)
0.78 (0.57–0.99) 21.79
ES (95% CI) % Weight (DL)
0.42 (0.35–0.49) 64.85
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Figure 2. Forest plot showing the effect of influenza vaccination on mortality and hospitalization. A, Effect of influenza vaccination on all-cause mortality. B, Effect of influ-
enza vaccination on all-cause mortality during influenza seasons. C, Effect of influenza vaccination on all-cause mortality during noninfluenza seasons. D, Effect of influenza 
vaccination on all-cause mortality in patients with heart failure and not chronic heart disease. E, Effect of influenza vaccination on heart failure hospitalization. Abbreviations: 
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preexisting heart failure. In terms of mortality, we found data 
favoring influenza vaccination in patients with heart failure. Our 
results suggest that the risk of all-cause mortality is 31% lower 
in the vaccinated individuals with heart failure, as compared 
with nonvaccinated patients. This effect is more prominent 
during influenza seasons compared with noninfluenza seasons 
(HR, 0.49 vs 0.79, respectively). In terms of hospitalization, we 
found a pooled hazard ratio of 0.62 favoring influenza vaccina-
tion, but this result did not reach statistical significance.
Importantly, we found that all-cause mortality is lower by 
almost one-third in patients with heart failure who received 
influenza vaccination, as compared with those who were not 
vaccinated. Our results are consistent with a retrospective co-
hort study of a population >75  years of age without baseline 
heart failure diagnosis [10] and with 2 recent meta-analyses in 
patients with underlying cardiovascular disease that showed 
50% [5] and 66% [29] reduction in cardiovascular deaths. 
Respiratory infection is a precipitating factor for heart failure 
exacerbation [9], and studies have repeatedly demonstrated 
the effectiveness of influenza vaccination in prevention of 
admissions secondary to influenza like illness and/or lower res-
piratory tract infection [30]. This decrease in mortality appears 
to be secondary to a decrease in heart failure exacerbations, and 
this finding is further supported by the larger decrease in mor-
tality during influenza seasons compared with noninfluenza 
seasons that we found in our analysis.
There was no statistically significant difference in the rate of 
hospitalization among vaccinated and nonvaccinated patients 
with heart failure (pooled HR of 0.62 favoring influenza vac-
cination), which may be due to the relatively limited number 
of studies. Furthermore, due to the low power of the included 
studies, small treatment effects could result in under- or over-
estimation of the treatment effect [31]. Moreover, individual 
studies have shown that admission secondary to heart failure 
or any cardiovascular cause or any other cause is less frequent 
among vaccinated individuals compared with nonvaccinated 
individuals [17, 22, 24, 25]. Similarly, studies have reported a 
decrease in the hospitalization rate after 1 year of influenza vac-
cination in elderly populations without baseline heart failure 
diagnosis [11, 12]. From an economic perspective, the total an-
nual direct medical cost burden from heart failure treatment in 
the United States was estimated to be $30.7 billion in 2012 [6] 
and is projected to reach $77.7 billion by 2030 [32]. A cost-ef-
fectiveness analysis reflecting current practices and costs is 
needed to address potential health care cost savings from influ-
enza vaccination in patients with heart failure.
Guidelines from professional societies in regards to the 
use of influenza vaccination have been explicit and uniform 
(Supplementary Table 1). The European Society of Cardiology 
(ESC) [33], the American College of Cardiology Foundation 
(ACCF) [34], and the CDC [35] recommend usage of influenza 
vaccines in patients with underlying cardiovascular disease, 
whereas the Heart Failure Society of America (HFSA) specif-
ically recommends the use of influenza vaccines in the heart 
failure population [36]. Despite this uniformity of published 
guidelines, the coverage rate remains low [37], and among the 
elderly population in the United States, the coverage rate has 
been constantly in the range of 60% to 65%, the latest being 
65.3% in the years 2016–2017 [38]. For example, in a large mul-
tinational trial among patients with heart failure, the vaccina-
tion coverage rate was <20% in more than half of the included 
countries, with the relevant rate in the United States being 
Table 2.  Study Outcomes (Mortality and Hospitalization)
S.No. First Author





HR Heart Failure All-Cause Cardiovascular
1. Kopel et al. 2014 [23] HR 1 y, 0.78 (0.60–1.02); 






2. Vardeny et al. 2016 
[25]
HR, 0.82 (0.7–0.96) 0.82 
(0.7–0.96)





3. Liu et al. 2012 [24] HR flu season, 0.42 (0.35–0.49); 
HR nonflu, 0.78 (0.68–0.9)
- 0.52 
(0.47–0.58)
- - HR flu, 0.84  
(0.76–0.93); 
HR nonflu, 1.04  
(0.91–1.18)
4. Diego et al. 2009 [21] HR flu season, 0.63 (0.44–0.91); 




5. Mohseni et al. 2017 
[17]
- - - IRR, 0.71  
(0.68–0.75)
IRR, 0.96  
(0.95–0.98)
IRR, 0.73  
(0.71–0.76)
6. Kaya et al. 2017 [22] - - - HR, 0.303  
(0.178–0.514)
- -
7. Blaya et al. 2016 [20] HR flu, 0.59; 
HR preflu, 0.91; 
HR postflu, 0.75
- - - - -
8. Wu et al. 2014 [26] OR, 0.75 (0.66–0.84) - - - - -
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barely above 50% [25]. Given the significant difference in mor-
tality among patients with heart failure who receive the vaccine, 
it will be important to identify factors that might contribute to 
the low compliance with the vaccination in this population and 
implement targeted strategies to increase the vaccination rate.
The findings of this meta-analysis should be interpreted 
while taking into account potential limitations. First, it should 
be noted that the studies are not randomized, and as such, our 
analysis is subject to the potential of “healthy user bias” and 
confounding factors. However, most of the studies included in 
our analysis were adjusted using the propensity score matching 
system, which adds validity to our results. Second, lower ejec-
tion fraction and higher New York Heart Association (NYHA) 
class are independent predictors of increased mortality in 
patients with heart failure [39, 40]. In our meta-analysis, in-
fluenza seemed to increase the mortality of patients with heart 
failure, but only 2 of the included studies reported the ejec-
tion fraction or the NYHA class of their patients. To account 
for the differences in the severity of heart failure in terms of 
ejection fraction and/or NYHA class, both studies performed 
multivariable logistic regression analysis [22, 25]. Future studies 
with stratification of heart failure severity are needed to min-
imize and avoid possible confounding. Third, optimal timing 
of vaccination is needed for maximum benefit [41], and this 
effect might also be influenced by the vaccine effectiveness, 
which changes every year [38]. To this effect, a random-effects 
model was selected to generate a more conservative estimate, 
and the large sample size (16 751 patients) included in the mor-
tality analysis strengthens our findings. Also, due to the limited 
number of included studies, we were not able to identify a cor-
relation between the yearly variability of vaccine effectiveness 
and outcomes such as mortality and hospitalization. Finally, in 
2 of the included studies, the study population consisted of both 
heart failure patients and patients with chronic heart disease. 
Although it is known that a large part of heart failure diagnosis 
is secondary to chronic heart disease like hypertension and cor-
onary heart disease [42], it would be ideal to compare the effect 
of influenza vaccination exclusively in a heart failure population 
and have undiluted results.
In conclusion, we report that in patients with heart failure, 
vaccination against influenza provides a statistically significant 
mortality benefit. This finding highlights the need for stricter 
implementation strategies of influenza vaccination in this pa-
tient population. Future studies should focus on identifying 
subgroups of patients who are less likely to be vaccinated, the 
effectiveness of high-dose vaccines, and the subgroups that 
will have the greatest benefit. Also, an updated cost-effective-
ness analysis should incorporate the potential benefit of influ-
enza vaccination, current practices, and the possible decrease in 
health care cost.
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